Try our beta test site
10 studies found for:    CAT-354
Show Display Options
Rank Status Study
1 Completed A Study to Assess Bioavailability and Pharmacokinetics of CAT 354
Condition: Healthy
Intervention: Drug: CAT-354
2 Completed Study to Evaluate the Safety and Efficacy of CAT-354
Condition: Asthma
Interventions: Drug: CAT-354;   Other: Placebo
3 Terminated
Has Results
A Study to Assess the Efficacy, Safety, and Tolerability of CAT-354 in Subjects With Asthma
Condition: Asthma
Interventions: Other: Placebo;   Biological: CAT-354 1 mg/kg;   Biological: CAT-354 5 mg/kg;   Other: CAT-354 10 mg/kg
4 Completed
Has Results
A Phase 1, Open-label Study to Investigate the Pharmacokinetics of Tralokinumab (CAT-354) in Adolescents With Asthma
Condition: Asthma
Intervention: Biological: Tralokinumab 300 mg
5 Completed A Study to Assess the Safety and Immunogenicity of the Drug CAT-354 in Healthy Japanese Subjects
Condition: Healthy
Interventions: Drug: CAT-354;   Drug: CAT 354
6 Completed A Study to Assess the Safety and Tolerability of Multiple Doses of Multi-Level of a Drug in Subjects With Moderate Asthma
Condition: Asthma
Interventions: Drug: CAT-354-0602;   Drug: Placebo
7 Completed
Has Results
Evaluation of Efficacy and Safety of Tralokinumab in Patients With Active, Moderate-to-severe Ulcerative Colitis
Condition: Ulcerative Colitis
Interventions: Drug: tralokinumab;   Drug: placebo
8 Completed D2212C00002 J-Phase II Study
Condition: Idiopathic Pulmonary Fibrosis
Interventions: Biological: tralokinumab cohort 1;   Biological: tralokinumab cohort 2;   Other: Placebo
9 Terminated A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis
Condition: Idiopathic Pulmonary Fibrosis
Interventions: Biological: Tralokinumab;   Other: Placebo
10 Completed A Phase 2b, Randomized, Double-blind Study to Evaluate the Efficacy of Tralokinumab in Adults With Asthma
Condition: Asthma
Intervention: Drug: Tralokinumab

Study has passed its completion date and status has not been verified in more than two years.